Publications
Detailed Information
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Lee, Jong Wook | - |
dc.contributor.author | Jung, Chul Won | - |
dc.contributor.author | Min, Chang Ki | - |
dc.contributor.author | Shin, Ho Jin | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Joo, Young Don | - |
dc.contributor.author | Kook, Hoon | - |
dc.contributor.author | Ahn, Hyo Seop | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Park, Hee-Sook | - |
dc.contributor.author | Min, Woo-Sung | - |
dc.contributor.author | Min, Yoo Hong | - |
dc.contributor.author | Sohn, Sang Kyun | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Kang, Hyoung Jin | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Chung, Joo Seop | - |
dc.contributor.author | Cho, Bin | - |
dc.date.accessioned | 2012-06-27T08:41:33Z | - |
dc.date.available | 2012-06-27T08:41:33Z | - |
dc.date.issued | 2010-11 | - |
dc.identifier.citation | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL; Vol.95 11; 1935-1942 | ko_KR |
dc.identifier.issn | 0390-6078 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77654 | - |
dc.description.abstract | Background Since it was suggested that B cells play a role in the pathogenesis of chronic graft-versus-host disease, rituximab, an anti-CD20 monoclonal antibody targeting B cells, has been shown to be effective in steroid-refractory, chronic graft-versus-host disease. However, most of the data were from small numbers of patients or retrospective analyses. We, therefore, conducted a multicenter phase II study to confirm the efficacy of this treatment strategy that targets B cells. Design and Methods We diagnosed and evaluated chronic graft-versus-host disease according to the National Institute of Health criteria for clinical trials on this condition. The treatment consisted of weekly intravenous infusions of rituximab for 4 weeks followed by monthly rituximab for 4 months. We evaluated the patients` responses and monitored their disease activity until their final visit, which was on day 365. We also assessed the patients` subsequent quality of life and serum levels of B-cell-activating factor of the tumor necrosis factor family. Results Among 37 patients enrolled (median age, 29 years; range 8-57 years), 32 patients responded to rituximab with 8 complete and 24 partial responses. Twenty-one patients maintained their response for 1 year, so their steroid treatment was discontinued or its dose reduced (21/37, or 56.8%), and their scores representing quality of life were improved although these changes were not statistically significant. The responses were better for clinical manifestations of the skin, oral cavity and musculoskeletal system (response rate, 71.4-100%) than for other organs. However, infectious complications and primary disease relapse accounted for the majority of treatment failure. The pre-treatment serum level of B cell-activating factor of the tumor necrosis factor family was not associated with better treatment outcome (P=0.147). Conclusions Rituximab could improve clinical responses and quality of life of patients with steroid-refractory chronic graft-versus-host disease, although such patients may need active prophylaxis against infection. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | FERRATA STORTI FOUNDATION | ko_KR |
dc.subject | rituximab | ko_KR |
dc.subject | steroid | ko_KR |
dc.subject | chronic graft-versus-host disease | ko_KR |
dc.subject | allogeneic stem cell transplantation | ko_KR |
dc.subject | quality of life | ko_KR |
dc.title | Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김석진 | - |
dc.contributor.AlternativeAuthor | 이종욱 | - |
dc.contributor.AlternativeAuthor | 정철원 | - |
dc.contributor.AlternativeAuthor | 민창기 | - |
dc.contributor.AlternativeAuthor | 조빈 | - |
dc.contributor.AlternativeAuthor | 신호진 | - |
dc.contributor.AlternativeAuthor | 정주섭 | - |
dc.contributor.AlternativeAuthor | 김학 | - |
dc.contributor.AlternativeAuthor | 이원식 | - |
dc.contributor.AlternativeAuthor | 주영돈 | - |
dc.contributor.AlternativeAuthor | 양덕환 | - |
dc.contributor.AlternativeAuthor | 국훈 | - |
dc.contributor.AlternativeAuthor | 강형진 | - |
dc.contributor.AlternativeAuthor | 안효섭 | - |
dc.contributor.AlternativeAuthor | 윤성수 | - |
dc.contributor.AlternativeAuthor | 손상균 | - |
dc.contributor.AlternativeAuthor | 민유홍 | - |
dc.contributor.AlternativeAuthor | 민우성 | - |
dc.contributor.AlternativeAuthor | 박희숙 | - |
dc.contributor.AlternativeAuthor | 원종호 | - |
dc.identifier.doi | 10.3324/haematol.2010.026104 | - |
dc.citation.journaltitle | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | - |
dc.description.citedreference | Teshima T, 2009, INT J HEMATOL, V90, P253, DOI 10.1007/s12185-009-0370-x | - |
dc.description.citedreference | Kharfan-Dabaja MA, 2009, BIOL BLOOD MARROW TR, V15, P1005, DOI 10.1016/j.bbmt.2009.04.003 | - |
dc.description.citedreference | Pidala J, 2009, BLOOD, V114, P7, DOI 10.1182/blood-2008-10-182592 | - |
dc.description.citedreference | Sarantopoulos S, 2009, BLOOD, V113, P3865, DOI 10.1182/blood-2008-09-177840 | - |
dc.description.citedreference | von Bonin M, 2008, TRANSPLANTATION, V86, P875, DOI 10.1097/TP.0b013e318183f662 | - |
dc.description.citedreference | Karanes C, 2008, BIOL BLOOD MARROW TR, V14, P8, DOI 10.1016/j.bbmt.2008.06.006 | - |
dc.description.citedreference | Kim SJ, 2008, EUR J HAEMATOL, V81, P177, DOI 10.1111/j.1600-0609.2008.01099.x | - |
dc.description.citedreference | Mohty M, 2008, BONE MARROW TRANSPL, V41, pS31 | - |
dc.description.citedreference | Sarantopoulos S, 2007, CLIN CANCER RES, V13, P6107, DOI 10.1158/1078-0432.CCR-07-1290 | - |
dc.description.citedreference | Zaja F, 2007, BONE MARROW TRANSPL, V40, P273, DOI 10.1038/sj.bmt.1705725 | - |
dc.description.citedreference | Cutler C, 2006, BLOOD, V108, P756, DOI 10.1182/blood-2006-01-0233 | - |
dc.description.citedreference | Copelan EA, 2006, NEW ENGL J MED, V354, P1813 | - |
dc.description.citedreference | Zhang CY, 2006, BLOOD, V107, P2993, DOI 10.1182/blood-2005-09-3623 | - |
dc.description.citedreference | Pavletic SZ, 2006, BIOL BLOOD MARROW TR, V12, P252, DOI 10.1016/j.bbmt.2006.01.008 | - |
dc.description.citedreference | Matsushita T, 2006, ARTHRITIS RHEUM, V54, P192, DOI 10.1002/art.21526 | - |
dc.description.citedreference | Okamoto M, 2006, LEUKEMIA, V20, P172, DOI 10.1038/sj.leu.2403996 | - |
dc.description.citedreference | Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004 | - |
dc.description.citedreference | Miklos DB, 2005, BLOOD, V105, P2973 | - |
dc.description.citedreference | CANNINGAVAN D, 2004, BLOOD, V104, P2603 | - |
dc.description.citedreference | Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P215, DOI 10.1053/bbmt.2003.50026 | - |
dc.description.citedreference | RATANATHARATHOR.A, 2003, BIOL BLOOD MARROW TR, V9, P505 | - |
dc.description.citedreference | Koc S, 2002, BLOOD, V100, P48 | - |
dc.description.citedreference | Ratanatharathorn V, 2001, BONE MARROW TRANSPL, V28, P121 | - |
dc.description.citedreference | Vogelsang GB, 2001, BLOOD, V97, P1196 | - |
dc.description.citedreference | Arora M, 2001, BIOL BLOOD MARROW TR, V7, P265 | - |
dc.description.citedreference | Ratanatharathorn V, 2000, ANN INTERN MED, V133, P275 | - |
dc.description.citedreference | Sutherland HJ, 1997, BONE MARROW TRANSPL, V19, P1129 | - |
dc.description.citedreference | WARE JE, 1994, SF 36 PHYS MENTAL HL | - |
dc.description.citedreference | SIMON R, 1987, CANCER TREAT REP, V71, P1079 | - |
dc.description.tc | 9 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.